Profile of glomerular diseases associated with hepatitis B and C: A single-center experience from India

Raveendran, N; Beniwal, Pankaj; Dsouza, Amith; Tanwar, Rajendra Singh; Kimmatkar, Piyush; Dk, Agarwal; Malhotra, Vinay

doi:10.4103/1319-2442.202761

Cited by 9 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 250-350 million people (5% of the world's population) are chronically HBV-infected, making it one of the most common human pathogens, [406][407][408] and about 3%-5% of patients with chronic HBV infection develop kidney disease as a complication. 409,410 The most common pattern of glomerular injury seen in HBV infection is MN. 411,412 Lesions of IgAN, membranoproliferative GN (MPGN), FSGS, and crescentic GN are seen less frequently.…”

Section: Hepatitis B Virus (Hbv) Infection-related Gnmentioning

confidence: 99%

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Rovin¹,

Adler²,

Barratt³

et al. 2021

Kidney International

1,059

883

View full text Add to dashboard Cite

S28 Introduction S30 Summary of recommendation statements and practice points S88 Chapter 1: General principles for the management of glomerular disease S115 Chapter 2: Immunoglobulin A nephropathy (IgAN)/immunoglobulin A vasculitis (IgAV) S128 Chapter 3: Membranous nephropathy S140 Chapter 4: Nephrotic syndrome in children S153 Chapter 5: Minimal change disease (MCD) in adults S161 Chapter 6: Focal segmental glomerulosclerosis (FSGS) in adults S172 Chapter 7: Infection-related glomerulonephritis S187 Chapter 8: Immunoglobulin-and complement-mediated glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury S193 Chapter 9: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis S207 Chapter 10: Lupus nephritis S231 Chapter 11: Anti-glomerular basement membrane (Anti-GBM) antibody glomerulonephritis S235 Methods for guideline development S243 Biographic and disclosure information S254 Acknowledgments S256 ReferencesThis guideline is published as a supplement supported by KDIGO. The development and publication of this guideline are strictly funded by KDIGO, and neither KDIGO nor its guideline Work Group members sought or received monies or fees from corporate or commercial entities in connection with this work. The opinions or views expressed in this professional education supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the International Society of Nephrology or Elsevier. Dosages, indications, and methods of use for products that are referred to in the supplement by the authors may reflect their clinical experience or may be derived from the professional literature or other clinical sources. Because of the differences between in vitro and in vivo systems and between laboratory animal models and clinical data in humans, in vitro and animal data may not necessarily correlate with clinical results.

show abstract

Section: Hepatitis B Virus (Hbv) Infection-related Gnmentioning

confidence: 99%

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Rovin¹,

Adler²,

Barratt³

et al. 2021

Kidney International

1,059

883

View full text Add to dashboard Cite

show abstract

Section: Hepatitis B Virus (Hbv) Infection-related Gnmentioning

confidence: 99%

KDIGO 2021 Clinical Practice Guideline for the Management of GLOMERULAR Diseases

Bobkova¹,

Bulanov²,

Zakharova³

et al. 2022

N&D

View full text Add to dashboard Cite

CURRENT CHRONIC KIDNEY DISEASE (CKD) NOMENCLATURE USED BY KDIGOCKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health. CKD is classified based on Cause, GFR category (G1-G5), and Albuminuria category (A1-A3), abbreviated as CGA.Green, low risk (if no other markers of kidney disease, no CKD); yellow, moderately increased risk; orange, high risk; red, very high risk. GFR, glomerular filtration rate

show abstract

“…It is membranous glomerulonephritis in 40% of cases, membranoproliferative glomerulonephritis in 20%, focal segmental glomerulosclerosis in 20%, IgA nephropathy in 10%; the remaining 10% account for the other forms. There are nephrotic syndrome in 60% of cases of HBV-associated glomerulonephritis, and nephritic syndrome or isolated changes in urine analysis in other cases[ 52 ].…”

Section: Hepatitis Bmentioning

confidence: 99%

Immune disorders and rheumatologic manifestations of viral hepatitis

Maslennikov¹,

Ивашкин²,

Efremova³

et al. 2021

WJG

View full text Add to dashboard Cite

Infection with hepatotropic viruses is not limited to the liver and can lead to the development of various immunological disorders (the formation of cryoglobulins, rheumatoid factor, antinuclear antibodies, autoantibodies specific for autoimmune hepatitis and primary biliary cholangitis, and others), which can manifest as glomerulonephritis, arthritis, uveitis, vasculitis (cryoglobulinemic vasculitis, polyarteritis nodosa, Henoch-Schonlein purpura, isolated cutaneous necrotizing vasculitis), and other rheumatologic disorders, and be a trigger for the subsequent development of autoimmune hepatitis and primary biliary cholangitis. A further study of the association between autoimmune liver diseases and hepatotropic virus infection would be useful to assess the results of treatment of these associated diseases with antiviral drugs. The relationship of these immune disorders and their manifestations with hepatotropic viruses is best studied for chronic hepatitis B and C. Only isolated cases of these associations are described for hepatitis A. These links are least studied, and are often controversial for hepatitis E, possibly due to their relatively rare diagnoses. Patients with uveitis, glomerulonephritis, arthritis, vasculitis, autoimmune liver diseases should be tested for biomarkers of viral hepatitis, and if present, these patients should be treated with antiviral drugs.

show abstract

Profile of glomerular diseases associated with hepatitis B and C: A single-center experience from India

Cited by 9 publications

References 1 publication

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

KDIGO 2021 Clinical Practice Guideline for the Management of GLOMERULAR Diseases

Immune disorders and rheumatologic manifestations of viral hepatitis

Contact Info

Product

Resources

About